» Articles » PMID: 33573698

Barriers to Completing Colonoscopy After a Positive Fecal Occult Blood Test

Overview
Publisher Biomed Central
Date 2021 Feb 12
PMID 33573698
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colorectal cancer leads to significant morbidity and mortality. Early detection and treatment are essential. Screening using fecal occult blood tests has increased significantly, but adherence to colonoscopy follow-up is suboptimal, increasing CRC mortality risk. The aim of this study was to identify barriers to colonoscopy following a positive FOBT at the level of the patient, physician, organization and policymakers.

Methods: This mixed methods study was conducted at two health care organizations in Israel. The study included retrospective analyses of 45,281 50-74 year-old members with positive fecal immunochemical tests from 2010 to 2014, and a survey of 772 patients with a positive test during 2015, with and without follow-up. The qualitative part of the study included focus groups with primary physicians and gastroenterologists and in-depth interviews with opinion leaders in healthcare.

Results: Patient lack of comprehension regarding the test was the strongest predictor of non-adherence to follow-up. Older age, Arab ethnicity, and lower socio economic status significantly reduced adherence. We found no correlation with gender, marital status, patient activation, waiting time for appointments or distance from gastroenterology clinics. Primary care physicians underestimate non-adherence rates. They feel responsible for patient follow-up, but express lack of time and skills that will allow them to ensure adherence among their patients. Gastroenterologists do not consider fecal occult blood an effective tool for CRC detection, and believe that all patients should undergo colonoscopy. Opinion leaders in the healthcare field do not prioritize the issue of follow-up after a positive screening test for colorectal cancer, although they understand the importance.

Conclusions: We identified important barriers that need to be addressed to improve the effectiveness of the screening program. Targeted interventions for populations at risk for non-adherence, specifically for those with low literacy levels, and better explanation of the need for follow-up as a routine need to be set in place. Lack of agreement between screening recommendations and gastroenterologist opinion, and lack of awareness among healthcare authority figures negatively impact the screening program need to be addressed at the organizational and national level.

Trial Registration: This study was approved by the IRB in both participating organizations (Meuhedet Health Care Institutional Review Board #02-2-5-15, Maccabi Healthcare Institutional Review Board BBI-0025-16). Participant consent was waived by both IRB's.

Citing Articles

The impact of multi-target stool DNA testing in clinical practice in the United States: A real-world evidence retrospective study.

Miller-Wilson L, Limburg P, Helmueller L, Janeiro M, Hartlaub P Prev Med Rep. 2022; 30:102045.

PMID: 36531100 PMC: 9747652. DOI: 10.1016/j.pmedr.2022.102045.


Effect of Bowel Preparation to Colonoscopy Interval on Preparation Quality and Colonoscopy Outcomes: A Meta-Analysis.

Gao Y, Lin X Turk J Gastroenterol. 2022; 34(1):26-34.

PMID: 36511605 PMC: 9984965. DOI: 10.5152/tjg.2022.22033.


Comorbidities and Risk Factors of Patients Diagnosed with CRC after Positive Fecal Test in Real Life.

Abu-Freha N, Gouldner R, Cohen B, Gordon M, Sagi O, Taha G Cancers (Basel). 2022; 14(22).

PMID: 36428650 PMC: 9688580. DOI: 10.3390/cancers14225557.


Barriers associated with inadequate follow-up of abnormal fecal immunochemical test results in a safety-net system: A mixed-methods analysis.

Issaka R, Bell-Brown A, Kao J, Snyder C, Atkins D, Chew L Prev Med Rep. 2022; 28:101831.

PMID: 35637893 PMC: 9144348. DOI: 10.1016/j.pmedr.2022.101831.

References
1.
Hibbard J, Stockard J, Mahoney E, Tusler M . Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004; 39(4 Pt 1):1005-26. PMC: 1361049. DOI: 10.1111/j.1475-6773.2004.00269.x. View

2.
Duncan A, Turnbull D, Wilson C, Osborne J, Cole S, Flight I . Behavioural and demographic predictors of adherence to three consecutive faecal occult blood test screening opportunities: a population study. BMC Public Health. 2014; 14:238. PMC: 4234274. DOI: 10.1186/1471-2458-14-238. View

3.
Rabeneck L, Tinmouth J, Paszat L, Baxter N, Marrett L, Ruco A . Ontario's ColonCancerCheck: results from canada's first province-wide colorectal cancer screening program. Cancer Epidemiol Biomarkers Prev. 2014; 23(3):508-15. DOI: 10.1158/1055-9965.EPI-13-0956. View

4.
Etzioni D, Yano E, Rubenstein L, Lee M, Ko C, Brook R . Measuring the quality of colorectal cancer screening: the importance of follow-up. Dis Colon Rectum. 2006; 49(7):1002-10. DOI: 10.1007/s10350-006-0533-2. View

5.
Doubeni C, Fedewa S, Levin T, Jensen C, Saia C, Zebrowski A . Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology. 2018; 156(1):63-74.e6. PMC: 6309478. DOI: 10.1053/j.gastro.2018.09.040. View